Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. 

CEO
Michael E. Severino
CEOMichael E. Severino
Employees
835
Employees835
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
835
Employees835

SRPT Key Statistics

Market cap
1.83B
Market cap1.83B
Price-Earnings ratio
-6.04
Price-Earnings ratio-6.04
Dividend yield
—
Dividend yield—
Average volume
2.40M
Average volume2.40M
High today
$17.70
High today$17.70
Low today
$17.09
Low today$17.09
Open price
$17.64
Open price$17.64
Volume
1.25M
Volume1.25M
52 Week high
$25.32
52 Week high$25.32
52 Week low
$14.68
52 Week low$14.68

Stock Snapshot

The current Sarepta Therapeutics(SRPT) stock price is $17.30, with a market capitalization of 1.83B. The stock trades at a price-to-earnings (P/E) ratio of -6.04.

As of 2026-10-06, Sarepta Therapeutics(SRPT) stock has fluctuated between $17.09 and $17.70. The current price stands at $17.30, placing the stock +1.2% above today's low and -2.3% off the high.

The Sarepta Therapeutics(SRPT)'s current trading volume is 1.25M, compared to an average daily volume of 2.4M.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $14.68 at its lowest and $25.32 at its peak.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $14.68 at its lowest and $25.32 at its peak.

SRPT News

Benzinga 7h
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock. HC Wainwright & Co. analyst Mit...

Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
Simply Wall St 19h
Two Stories Ran On Sarepta Therapeutics. Only One Held Up - Simply Wall Street

...

Two Stories Ran On Sarepta Therapeutics. Only One Held Up - Simply Wall Street
TipRanks 1d
Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bearish stance on SRPT stock, giving a Sell rating on September 28. Mitchell Kapoor has given his...

Analyst ratings

50%

of 24 ratings
Buy
29.2%
Hold
50%
Sell
20.8%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.